476060.KQ
Price:
$14520
Market Cap:
$160.69B
Onconic Therapeutics, Inc. operates as a biopharmaceutical enterprise, primarily dedicated to the discovery and advancement of novel therapeutic solutions. Its research and development initiatives principally focus on creating new medications for acid-related ailments and various oncological conditions. This company was established on May 7, 2020, and maintains its principal office in Seoul, South Korea.
Industry
Biotechnology
IPO Date
2024-12-19
Stock Exchange
KOE
Ticker
476060.KQ
According to Onconic Therapeutics’s latest financial reports and current stock price. The company's current ROE is 31.68%. This represents a change of 288.86% compared to the average of 8.15% of the last 4 quarters.
The mean historical ROE of Onconic Therapeutics over the last ten years is 50.92%. The current 31.68% ROE has changed -37.79% with respect to the historical average. Over the past ten years (40 quarters), 476060.KQ's ROE was at its highest in in the March 2024 quarter at 51.79%. The ROE was at its lowest in in the June 2024 quarter at -23.99%.
Average
50.92%
Median
21.91%
Minimum
-14.45%
Maximum
189.89%
Discovering the peaks and valleys of Onconic Therapeutics ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 69.06%
Maximum Annual ROE = 189.89%
Minimum Annual Increase = -251.67%
Minimum Annual ROE = -14.45%
| Year | ROE | Change |
|---|---|---|
| 2025 | 21.91% | -251.67% |
| 2024 | -14.45% | 69.06% |
| 2023 | -8.54% | -112.99% |
| 2022 | 65.79% | -65.35% |
The current ROE of Onconic Therapeutics (476060.KQ) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-0.36%
5-year avg
50.92%
10-year avg
50.92%
Onconic Therapeutics’s ROE is less than Macrogen, Inc. (6.66%), greater than MedPacto, Inc. (-32.04%), greater than Amicogen, Inc. (-17.31%), greater than GeneOne Life Science, Inc. (-76.96%), greater than IMBdx (-31.84%), less than EASY BIO,Inc. (33.44%), greater than Encell Co. Ltd. (-44.31%), less than GC Genome Corporation (0%), less than CG Invites Co., Ltd. (0.47%), greater than HANDOK Inc. (-1.63%),
| Company | ROE | Market cap |
|---|---|---|
| 6.66% | $135.52B | |
| -32.04% | $87.40B | |
| -17.31% | $56.92B | |
| -76.96% | $48.42B | |
| -31.84% | $43.22B | |
| 33.44% | $203.78B | |
| -44.31% | $62.71B | |
| 0% | $127.48B | |
| 0.47% | $61.52B | |
| -1.63% | $121.73B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Onconic Therapeutics using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Onconic Therapeutics or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Onconic Therapeutics's ROE?
How is the ROE calculated for Onconic Therapeutics (476060.KQ)?
What is the highest ROE for Onconic Therapeutics (476060.KQ)?
What is the 3-year average ROE for Onconic Therapeutics (476060.KQ)?
What is the 5-year average ROE for Onconic Therapeutics (476060.KQ)?
How does the current ROE for Onconic Therapeutics (476060.KQ) compare to its historical average?